Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

Cell therapy for diabetes: New data, approval, buyout; GLP-1 race in weight loss reaches new stage; FDA finally approves BioMarin’s gene therapy; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit

July 2, 2023

Trump campaign provides new details on his ear wound and treatment

WASHINGTON — Former President Donald Trump is doing well and required no stitches after a gunshot at his campaign rally last weekend grazed his ear,

July 20, 2024

Officials agree: Use settlement funds to curb youth addiction. But the ‘how’ gets hairy.

When three teenagers died of fentanyl overdoses last year in Larimer County, Colorado, it shocked the community and “flipped families upside down,” said Tom Gonzales,

September 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.